Capital Advisors Ltd’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-21
Closed -$2K 1436
2025
Q4
$2K Hold
21
﹤0.01% 1074
2025
Q3
$1K Hold
21
﹤0.01% 1183
2025
Q2
$1K Buy
21
+9
+75% +$457 ﹤0.01% 1181
2025
Q1
$1K Hold
12
﹤0.01% 1169
2024
Q4
$1K Hold
12
﹤0.01% 1192
2024
Q3
$1K Hold
12
﹤0.01% 1189
2024
Q2
$1K Sell
12
-4
-25% -$220 ﹤0.01% 1173
2024
Q1
$1K Buy
16
+4
+33% +$253 ﹤0.01% 1174
2023
Q4
$1K Hold
12
﹤0.01% 1126
2023
Q3
$1K Hold
12
﹤0.01% 1118
2023
Q2
$1K Sell
12
-33
-73% -$2.57K ﹤0.01% 1130
2023
Q1
$3K Buy
45
+33
+275% +$2.12K ﹤0.01% 802
2022
Q4
$1K Sell
12
-29
-71% -$1.19K ﹤0.01% 986
2022
Q3
$1K Buy
+41
New +$1.69K ﹤0.01% 1008
2022
Q1
Sell
-3
Closed 988
2021
Q4
$0 Buy
+3
New +$265 ﹤0.01% 852

Other funds holding EXAS

Capital Advisors Ltd's EXAS Position: Q1 2026 in Review

Capital Advisors Ltd sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 21 shares — an estimated $2K sold.

Capital Advisors Ltd first reported a position in EXAS in Q4 2021 and held it in 15 quarters. The position peaked at $3K in Q1 2023. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Capital Advisors Ltd reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Capital Advisors Ltd sold 21 Exact Sciences shares in Q1 2026, an estimated $2K.
  • Capital Advisors Ltd first reported a position in Exact Sciences in Q4 2021 and held it in 15 quarters.
  • Capital Advisors Ltd's Exact Sciences position peaked at $3K in Q1 2023.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Capital Advisors Ltd's 13F filing for Q1 2026, filed 16 Apr 2026.